Navigation Links
Molecular Profiles Joins Leading Consortium To Drive Paediatric Formulation Development
Date:12/19/2013

NOTTINGHAM, England, Dec. 19, 2013 /PRNewswire/ --A collaborative pharmaceutical project focused on improving the pathway for developing paediatric formulations has been given the go-ahead after successfully securing an innovation grant.

The UK-wide consortium, led by Astra Zeneca, received a £660k grant from the UK's innovation agency, the Technology Strategy Board, to help fund a £1million project aimed at accelerating paediatric formulation development through smart design and predictive science.

The consortium is comprised of pharmaceutical analytical development specialist Molecular Profiles along with Pfizer, Bristol Myers Squibb, GlaxoSmithKline and academic institutions including University College London, University of Bath, University of Birmingham, Aston University and the Academy of Pharmaceutical Sciences (a not-for-profit organisation).

Paediatric formulation development is more complex than the associated adult medicines. In addition to considering the differences in physiology and anatomy, paediatric formulations must offer flexible dosing and provide effective taste-masking.

This project will address the need to improve the speed, cost and quality of paediatric formulation development by drawing on the combined expertise of the consortium members. The goal is to deliver a novel, commercially available, regulatory-approved platform to identify the most appropriate delivery strategy.

Molecular Profiles' chief executive officer Nikin Patel said: "This collaborative project is an ambitious venture aimed at developing a strategic pathway to expedite the development of paediatric formulations, establishing the UK as a global leader in this area. Receipt of the Technology Strategy Board grant will enable us to move forward with this multi-partner project.

"To be involved with such credible consortium members from both large pharmaceutical companies and academia is exciting for Molecular Profiles. Our team is ready to apply our expertise to assist the consortium in achieving its collective goals," concluded Dr. Patel.

The government-backed Technology Strategy Board has awarded over £9.2 million to support 35 collaborative projects to advance the UK's capabilities in formulated products. The funding allocated through the Formulated products - meeting the product and process design challenge was shared across 19 feasibility projects and 16 collaborative R&D projects. The initial funding was increased by 50% due to the strength of submissions.

Molecular Profiles works with leading pharmaceutical companies across the globe and specialises in advanced characterisation, R&D, formulation development and clinical manufacturing services. Its team has specialist knowledge on developing challenging molecules and manufacturing a range of dosage forms spanning solids, liquids, semi-solids and inhaled products, including highly potent compounds.  Molecular Profiles is a wholly-owned subsidiary of Columbia Laboratories, Inc. (Nasdaq: CBRX).

www.molprofiles.co.uk/ | enquiry@molprofiles.co.uk | https://twitter.com/MolProfiles

Notes for editors:

The Technology Strategy Board is the UK's innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org.

About Columbia Laboratories
Columbia Laboratories, Inc. is a profitable company with a rich heritage in drug development. The Company's revenue streams include sales and royalty revenues from CRINONE® 8% (progesterone gel), which is marketed by Actavis, Inc. in the United States and by Merck Serono S.A. in over 60 other countries worldwide, and revenues from its wholly-owned subsidiary Molecular Profiles Ltd., a UK-based provider of pharmaceutical formulation development and manufacturing services. For more information, please visit www.columbialabs.com.

Molecular Profiles™ is a registered trademark of Molecular Profiles Ltd.


'/>"/>
SOURCE Columbia Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. QIAGEN and Cardinal Health Collaborate to Offer Molecular Diagnostic Products to Smaller and Mid-sized U.S. Hospitals
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
4. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
5. The 2012 US Molecular Diagnostics Market
6. BSGI Molecular Breast Imaging Provides Better Results than MRI for Cancer Patients with Dense Breasts
7. BSGI Molecular Breast Imaging Proves Equivalent to MRI in Breast Cancer Patient Management
8. Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting
9. Science Translational Medicine and the DMM Global Foundation Announce Days of Molecular Medicine 2012 "The Translational Science of Rare Diseases: From Rare To Care."
10. IBA Molecular, Piramal Imaging Sign Agreement for New F-18 Amyloid Imaging Agent
11. New Molecular Assay Allows Healthcare Facilities to Simplify Active Surveillance Testing for Deadly Superbug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... FDA 510(k) clearance covers Confocal Miniprobes ... and surgical applications Mauna Kea Technologies ... multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced ... the 12 th 510(k) clearance from United ... FDA clearance covers Confocal Miniprobes indicated for use ...
(Date:5/25/2016)... , May 25, 2016 According ... by Type (3D, 2D, 4D), by Therapeutic Area (Oncology, ... End User (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast ... global Medical Animation Market for the forecast period of ... USD 301.3 Million by 2021 from USD 117.3 Million ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, ... Therawis bedient dringenden Bedarf ... QIAGEN N.V. (NASDAQ: QGEN ; ... Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur ... eingegangen zu sein. Ein erstes Projekt wird die ...
Breaking Medicine Technology:
(Date:5/25/2016)... RHINEBECK, NY (PRWEB) , ... May 25, 2016 , ... ... announced the launch of 11 innovative workshops and training opportunities in the ... to the unique needs of individuals who are dealing with specific health issues—including injuries, ...
(Date:5/25/2016)... ... ... The Global Wellness Summit (GWS) today announced that its 2016 agenda will ... continent that pioneered the medical/wellness concept for the world. , Delegates to the 10th ... Henri Chenot, Founder of the Chenot Group, which operates wellness centers around the world ...
(Date:5/25/2016)... ... 25, 2016 , ... Conrad Siegel Actuaries, delivering comprehensive employee ... Drug survey , an employee benefits survey measuring how Central PA ... 2015, indicates that employers are turning to consumer directed health care and are ...
(Date:5/25/2016)... , ... May 25, 2016 , ... Laser Skin ... help turn back the hands of time of female aging. The Juliet™ ... Women with symptoms such as leakage, laxity, itchiness and pain have reported real ...
(Date:5/25/2016)... ... 25, 2016 , ... Consumer access to organic foods and grower access to ... of whole grain cereals and other plant-based foods, will introduce the first consumer product ... wheat processed by Hesco/Dakota Organic Products. , The transitional designation means the cereal was ...
Breaking Medicine News(10 mins):